ARDELYX, INC. Impairment of Long-Lived Assets Held-for-use
ARDELYX, INC. (ARDX) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2023-03-02
- ARDELYX, INC. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
- ARDELYX, INC. impairment of long-lived assets held-for-use for fiscal 2021 was $0.00.
- ARDELYX, INC. impairment of long-lived assets held-for-use for fiscal 2020 was $0.00.
- ARDELYX, INC. impairment of long-lived assets held-for-use for fiscal 2019 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 12 month | Impairment of Long-Lived Assets Held-for-use 36 month |
|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-02 | |
| 2021-12-31 | $0.00 10-K · filed 2023-03-02 | |
| 2020-12-31 | $0.00 10-K · filed 2023-03-02 | |
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 | $0.00 10-K · filed 2020-03-06 |
| 2018-12-31 | $0.00 10-K · filed 2021-03-08 | |
| 2017-12-31 | $0.00 10-K · filed 2018-03-14 | |
| 2016-12-31 | $0.00 10-K · filed 2017-02-17 | |
| 2015-12-31 | $0.00 10-K · filed 2016-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |